Real-World Precision Medicine: Proteogenomics to Accelerate Drug Development and Patient Care

Join us at this Pre-Congress webinar. 

Ever since the announcement of the Precision Medicine Initiative, there have been increasing efforts to identify and understand the basis of cancer using high-throughput technologies and the development of specialized treatments for specific subtypes of cancer, based on molecular evidence. Clinical proteogenomics is an exciting opportunity to complement the gene testing-centric clinical community for precision medicine. However, translating proteomic measurements to real-world patient care requires synergy of multiple requirements: meaningful and actionable molecular characterization, clinical and analytical validation, defining diagnosis values, and meeting regulatory compliance.

This HUPO session showcases clinical researchers discussing their stories and strategies to move proteomics towards better patient/clinical care. During this interactive broadcast, learn about the insight of three stories:

• Microscaled proteogenomics technology for predicting response of triple negative breast cancer
• Development of robust targeted platforms for clinical laboratory tests, drug development, and clinical trials

New Prospects for Killing ER+ Breast Cancer (Micro-scale Proteogenomics)

• Speaker: Matthew Ellis, MB., BChir., Ph.D., FRCP 
• Overall: Dr. Ellis will discuss how microscaled proteogenomics is applied to biopsies from triple negative breast cancer patients undergoing neoadjuvant carboplatin/docetaxel, revealing a wealth of biological features associated with chemotherapy resistance beyond immune response markers.

Building New Clinical Solutions for Precision Oncology via Proteogenomics

• Speaker: Amanda Paulovich, MD, PhD
• Overview: Dr Paulovich will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology, and summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into clinical trials and the clinical laboratory

Title TBC

• Speaker: Albert Sickmann, PhD 

Webinar Registration